GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » Research & Development

Lavipharm (ATH:LAVI) Research & Development : €0.39 Mil (TTM As of Jun. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lavipharm Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Lavipharm's Research & Development for the six months ended in Jun. 2024 was €0.20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €0.39 Mil.

Lavipharm Research & Development Historical Data

The historical data trend for Lavipharm's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm Research & Development Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 0.74 0.75 0.81 0.85 0.43

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.38 0.47 0.24 0.19 0.20

Lavipharm Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm  (ATH:LAVI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lavipharm Research & Development Related Terms

Thank you for viewing the detailed overview of Lavipharm's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Lavipharm Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » Research & Development
Comparable Companies
BSE:PTR BSE:ARS BSE:TRANSI BSE:CMF BSE:ATB BSE:EVER BSE:COTE BSE:SCD BSE:VNC BSE:RMAH ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
BXA0:Germany
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Website
http://www.lavipharm.com
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes innovative, safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm Headlines

No Headlines